Researchers have identified potential drug targets in glioblastoma cancer stem cells, providing a new approach to treat this aggressive brain cancer. By analyzing stem cells derived from patient tumors, scientists found two primary cell subtypes responsible for tumor growth, each with unique vulnerabilities.
